BBP

A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus.Firms are forging ahead with testing, treatment and vaccine research and product development.Results of even the most promising treatments, however, are not yet clear cut. Even those that may be are not proof a bullish thesis for those companies that have developed them.Biotech investing is risky. The temptations of building a large position in a COVID 19-engaged public company are obvious.A wise investor would be well-served by opening or adding to such positions with a measure of caution.